ABEO: צמיחה צפויה ברווח למניה לשנה הבאה Abeona Therapeutics Inc.

Abeona Therapeutics (ABEO) management is currently actively scaling production capacities to bring its key product to market. The shift in the consensus net profit growth estimate visualizes these expectations, where the value of 54.40 corresponds to the current metric. The primary momentum is driven by the anticipated FDA approval of Pz-cel. Strong protection against dumping and exclusive sales rights guarantee the company a stable position within the orphan diseases niche.
פילוחים אנליטיים ודוחות נתונים של חברת Abeona (ABEO)

This indicator assesses the expected dynamics of earnings per share, reflecting market expectations for business growth rates. By analyzing the consensus forecast for forward-looking EPS growth, an investor determines the probability of an asset valuation adjustment. The calculation is based on the aggregation of analysts' projected earnings relative to the current period. For Abeona Therapeutics (ABEO), this trend depends directly on the success of gene therapy and the volume of government grants.